CXCL8 and neoplasm: Our study demonstrates that miR-23a is a critical determinant of NPC radioresponse, its expression level in the primary tumor can be used for predicting radioresponse of NPC patients, and targeting miR-23a/IL-8/Stat3 signaling might be a promising approach for enhancing NPC sensitivity to radiotherapy.